Loading clinical trials...
Loading clinical trials...
Experiences Among Family Members, Carers and Significant Others of Brief Admission by Self-referral for Self-harming and Suicidal Persons: a Qualitative Study
As a result of a randomized controlled trial (NCT02985047) BA is continuously offered to persons with self-harm at risk for suicide in Skåne, Sweden. This qualitative inductive study aims to provide experiences among family members, carers and significant others of Brief Admission by self-referral for self-harming and suicidal persons based on individual semi-structured interviews. Participants will be identified through suggestion from persons with an active BA contract. Interviews, estimated to last 30-60 minutes, will be analyzed by a phenomenological hermeneutic method or by content analysis depending on richness and depth in the interviews. Findings from this study will be published.
As a result of the randomized controlled trial evaluating BA in Skåne (NCT02985047), BA is since January 2019, continuously offered to persons with self-harm at risk for suicide in Skåne, Sweden. Parallel to the clinical trial qualitative interview studies have been performed on the experiences of BA, with participants during the pilot phase of the trial and among the most severely ill persons and from the viewpoint of psychiatric staff. The present study aims to complement the above-mentioned studies with analysis of real-life experiences of BA from the perspective of loved ones to persons with current access to BA. This is important since the persons close to those suffering from recurrent self-harm and suicidal ideation play an essential role in times of crisis and may beneficially contribute to motivation as well as effects of provided care. In this qualitative inductive study individual semi-structured interviews will be held with family members, carers and significant others of persons with an active BA contract, who has given informed consent to participate. To identify potential informants, persons with an active BA contract, who have used BA within the last three months, at the wards in Lund, Malmö, Helsingborg or Kristianstad will be contacted and asked about contact information (name and telephone number) to a person close to them who may be contacted regarding inclusion in the present study. A variation of contract length (minimum one month since first signed contract) is strived for. The number of interviews will depend on the number of active contracts at the included wards and the proportion of those where potential participants may be contacted and who subsequently consent to participate, but with a maximum of 25 interviews. Interviews are estimated to be 30-60 minutes, and will be conducted in a calm place, chosen by the participant. Interviews will be performed by doctoral students in psychiatry and supervised by a senior researcher with experience of psychiatry and qualitative research. Interviews will be transcribed and analyzed by a phenomenological hermeneutic method or by content analysis depending on richness and depth in the interviews. Findings from this study will be published.
Age
18 - 100 years
Sex
ALL
Healthy Volunteers
No
Psykiatri och habilitering, Region Skåne
Lund, Skåne County, Sweden
Start Date
June 1, 2021
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2023
Last Updated
January 31, 2024
14
ACTUAL participants
Semi-structured interviews
OTHER
Lead Sponsor
Region Skane
Collaborators
NCT07025720
NCT07432438
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions